Abstract 661P
Background
CY-101 is a synthetic peptide that inhibits the oncogenic Wnt/β-catenin pathway by activating Axin2 and has a pore-forming membranolytic effect on cancer cells that triggers a tumor-specific immune response. Here, we report findings from a phase I/IIa trial evaluating intratumoral (IT) administration of CY-101 monotherapy and in combination with pembrolizumab in patients (pts) with heavily pretreated advanced solid tumors.
Methods
Eligible pts received biweekly (Q2W) IT injections with CY-101 into 1-3 accessible metastatic lesion(s). The primary endpoint was safety and tolerability, with anti-tumor and immunomodulatory activity as secondary objectives. Dose-escalation (2, 8, and 20 mg) followed a ‘3+3 design’ with a 6-week dose-limiting toxicity (DLT) observation period. The recommended dose for further development (R2PD) was explored across three expansion cohorts: A) CY-101 Q2W monotherapy, B) CY-101 plus pembrolizumab 400 mg Q6W, and C) CY-101 Q2W monotherapy in intrahepatic lesions. Response assessment was performed every 8 weeks.
Results
No DLTs were observed in the dose escalation part. The R2PD was defined at 20 mg. In the dose-expansion phase, 45 pts were enrolled among the 3 cohorts A (n=18), B (n=15), and C (n=12). Common grade 1-2 treatment-related adverse events (TRAE) included pain at the injection site (63.6%), fatigue (20.1%), pyrexia (11.4%) and injection site reaction (9.1%). One grade 3 TRAE, due to pain related to IT administration (2.2%), was noted. Histopathologic examination of post-treatment biopsies revealed enlarged necrotic areas and tumor infiltrating lymphocytes in 70%. Across tumor types, the disease control rate was 31%, with 36% having an ongoing response beyond six months. Abscopal partial responses were seen in three pts (2 monotherapy, 1 combination). Notably, among six pts with adrenocortical carcinoma (monotherapy), a disease control rate of 50% (n = 3/6) was observed, with durable responses (> 6 months) in two pts. Both pts expressed β-catenin (IHC) and had somatic mutations in the Wnt/β-catenin pathway (WES).
Conclusions
CY-101 is well tolerated at the RP2D of 20 mg and demonstrated early signs of antitumor activity, especially in tumors with dysregulated Wnt/β-catenin signaling.
Clinical trial identification
NCT04260529; Release date: 05-02-2020.
Editorial acknowledgement
Legal entity responsible for the study
Cytovation AS.
Funding
Cytovation ASA.
Disclosure
S. Champiat: Non-Financial Interests, Institutional, Invited Speaker: Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Genmab, Janssen, Merck, MSD, Novartis, Roche, Servier, Takeda; Non-Financial Interests, Institutional, Principal Investigator: AbbVie, Amgen, Boehringen Ingelheim, Bolt, Biotherapeutics, Centessa Pharmaceuticals, Cytovation, Eisai, GSK, Imcheck Therapeutics, Immunocore, Molecular Partners Ag, MSD, Ose Immunotherapeutics, Pierre Fabre, Replimune, Roche, Sanofi Aventis, Seagen, Sotio AS, Transgene; Non-Financial Interests, Institutional, Advisory Board: Acces Trial, Alderaan Biotechnology, Amgen, AstraZeneca, Avacta, BeiGene, BioNTech, Celanese, Domain Therapeutics, Ellipses Pharma, Genmab, Harpoon therapeutics, Immunicom, Inc., Mariana Oncology, Mima Health, Nanobiotix, Nextcure, Oncovita, Pierre Fabre, Seagen, Takeda, Tatum Bioscience, Tollys, UltraHuman8, UltraHuman8. V. Moreno Garcia: Financial Interests, Personal, Advisory Board: BMS, Janssen, Roche, Basilea, Bayer, AstraZeneca; Financial Interests, Personal, Full or part-time Employment: START; Financial Interests, Institutional, Local PI, AbbVie, AceaBio, Adaptimmune, ADC Therapeutics, Aduro, Agenus, Amcure, Amgen, Astellas, AstraZeneca Bayer BeiGene BioInvent International AB, BMS, Boehringer, Boheringer, Boston, Celgene, Daiichi Sankyo, Debiopharm, Eisai, e-Terapeutics, Exelisis, Forma Therapeutics, Genmab, GSK, Harpoon, Hutchison, Immutep, Incyte, Inovio, Iovance, Janssen, Kyowa Kirin, Lilly, Loxo, MedSir, Menarini, Merck, Merus, Millennium, MSD, Nanobiotix, Nektar, Novartis, Odonate Therapeutics, Pfizer, PharmaMar, Principia, PsiOxus, Puma, Regeneron, Rigontec, Roche, Sanofi, Sierra Oncology, Synthon, Taiho, Takeda, Tesaro, Transgene, Turning Point Therapeutics, Upshersmith: Multiple. F. Opdam: Non-Financial Interests, Principal Investigator: GSK, Int1B3, AstraZeneca, Cytovation, Relay, Taiho, Roche, Merus, Boehringer ingelheim, Crescendo, Pierre Fabre, Lilly, RevMed, Incyte. H. Gelderblom: Financial Interests, Institutional, Local PI: Deciphera, Cytovation; Financial Interests, Institutional, Coordinating PI: Boehringer Ingelheim, AmMax Bio, Debiopharm, Abbisko. M. Chaney: Financial Interests, Personal, Full or part-time Employment: Merck and Co., Inc; Financial Interests, Personal, Stocks/Shares: Merck and Co., Inc; Non-Financial Interests, Member: ASCO, AACR. L. Prestegarden: Financial Interests, Personal, Full or part-time Employment: Cytovation. All other authors have declared no conflicts of interest.
Resources from the same session
640P - Tumor response rate for hematologic and solid cancer drugs with FDA approval supported by single-arm trials
Presenter: Daniel Michaeli
Session: Poster session 01
641P - Phase I/II clinical and pharmacokinetic study of ecubectedin in combination with irinotecan in patients with selected advanced solid tumors
Presenter: Ana Gil Torralvo
Session: Poster session 01
642P - Phase I study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLC
Presenter: Qing Zhou
Session: Poster session 01
644P - Preliminary results of GQ1005 in metastatic HER2-low expressing breast cancer and HER2 positive gastric cancer
Presenter: Ting Deng
Session: Poster session 01
645P - Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors
Presenter: Dazhi Liu
Session: Poster session 01
646P - A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
Presenter: Christopher Twelves
Session: Poster session 01
Resources:
Abstract
647P - EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase I/II study
Presenter: Elisa Fontana
Session: Poster session 01
649P - Phase I study of SHR-A2102, a nectin-4 targeted ADC, in patients with advanced solid tumors
Presenter: Hua Zhong
Session: Poster session 01
650P - Initial results from a phase I/II study of BT7480, a novel nectin-4/CD137 bicycle tumor-targeted immune cell agonist, in patients (pts) with advanced solid tumors
Presenter: Kyriakos Papadopoulos
Session: Poster session 01